This article is part of our monthly series where we highlight five large-cap, relatively safe, divid

Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026. Sanofi announc

Sanofi is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewa

NEW YORK--(BUSINESS WIRE)--Weitz & Luxenberg, which represents more people in the Dupixent litigatio

The six-time NBA All-Star, three-time All-NBA selection, 2016 NBA Rookie of the Year, and 2026 NBA C

SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammatio

Regeneron and Sanofi announced a strategic expansion of their antibody collaboration, targeting IL-4

Regeneron and Sanofi expand their 20-year antibody collaboration with a $1 billion upfront payment a

Regeneron Pharmaceuticals NASDAQ: REGN and Sanofi said they are expanding their long-running collabo

Regeneron and Sanofi NASDAQ: SNY announced an expanded collaboration focused on developing next-gene

The companies will share development and commercialization costs as well as potential future profits

REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regenero

French drugmaker ​Sanofi said on Thursday it ‌would pay US partner Regeneron $1 billion upfront and

REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regenero

Sanofi and Regeneron expand global Alliance with multiple nex t-generation, long-acting immunology a

GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and

SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth

Sanofi (NASDAQ: SNY) is reviewing its late-stage pipeline, broadening its business-development lens

Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Sanofi NASDAQ: SNY is reviewing its late-stage pipeline, broadening its business-development lens an

Sanofi NASDAQ: SNY is prioritizing continued growth in Specialty Care while preparing for the loss o

Sanofi (NASDAQ:SNY) reported second-quarter financial results on Thursday. The transcript from the c

Novo Nordisk taps Anthropic AI to speed medicine research, enhance software workflows, and implement

The $925 million (CAD) expansion is adding end-to-end vaccine manufacturing capacity on Canadian soi

Q2 strengthened earnings visibility, with higher guidance and continued Dupixent momentum supporting

Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutini

FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligi

Oz says the MMR vaccine is “not a lethal vaccine” after Trump warned the combined shot could be “qui

Sanofi withdrew its Dupixent application for bullous pemphigoid on June 24, 2026, due to unresolved

President Donald Trump signed an order Monday limiting core childhood vaccine recommendations to 11

https://youtu.be/H_RititNE8U

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the d

Sanofi (SNY) Q2 sales hit $13.48B, beating estimates driven by Dupixent's 37.6% surge. Full deta

Sanofi (NASDAQ:SNY) reported quarterly earnings of $1.21 per share which beat the analyst consensus

Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety da

Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as cri

FDA approves Sanofi’s Sarclisa Escena, the first subcutaneous multiple myeloma treatment administere

The US Food and Drug Administration (FDA) has approved subcutaneous (SC) Sarclisa (isatuximab-irfc)

Sino Biopharma expanded its GSK partnership in China and signed an AstraZeneca licensing deal worth

Sanofi says Nexviazyme met all Phase 3 trial endpoints in infantile Pompe disease, supporting a plan

Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3

EU opens antitrust probe into Sanofi over claims it disparaged rival flu vaccine Fluad in Germany an

AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its

Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read

Owkin and Sanofi expand their AI partnership with a five-year deal to develop agentic systems aimed

Inhibrx explores spin-off of INBRX-106 amid Big Pharma interest, with potential valuation exceeding

Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to

Trump, in January, said "inflation has been defeated." Wall Street is now bracing for a 0.9%

Sanofi reports positive Phase 2 data for lunsekimig in asthma and nasal polyps, while atopic dermati